

De la quimioterapia al tratamiento target: la personalización del tratamiento en oncología

Federico Losco
GU Oncology




Que intento lograr en los pacientes con cáncer


Una relación humana significativa.

Tratar los síntomas.

Curar.



Calidad y cantidad de vida.






1941



Supresión hormonal






1947

Antimetabolitos



1949

Mostazas nitrogenadas




11 %
de las muertes
por t. sólidos en
hombres
entre 25 a 34 a.



0.1 %
de las muertes
por t. sólidos en
hombres
entre 25 a 34 a.

 Anticuerpos
 Quimioterapia




1900 pacientes por


mes
Instituto Hospital de Dia IAF 2023

1997


Rituxima **b**




Apoptosis mediada por NK




Citotoxicidad mediada por complemento



Citotoxicidad celular




Fagocitosis dependiente de anticuerpos




1998

Trastuzuma b







Desarrollo de terapias anti Her2



2001

Imatinib





Medicina de precisión



Estrategias clínicas, terapéuticas y diagnósticas para el manejo óptimo basado en variaciones individuales en el perfil genético del paciente.

Cambio de paradigma en el tratamiento



Biomarker Findings

Tumor Mutational Burden - 23 Muts/Mb
Microsatellite status - MS-Stable

Genomic Findings

For a complete list of the genes assayed, please refer to the Appendix.

- BRCA1 rearrangement intron 4, E1765*
- ERBB2 amplification
- NF1 Q400*
- PIK3CA E545K
- RICTOR amplification
- CRKL amplification - equivocal†
- EP300 S1754*, Q1379*
- EPHA3 amplification
- JUN amplification
- MAPK1 amplification - equivocal†
- TERT promoter -146C>T

† See About the Test in appendix for details.

Report Highlights

- Targeted therapies with NCCN categories of evidence in this tumor type: Pembrolizumab (p. 11)
- Evidence-matched clinical trial options based on this patient’s genomic findings: (p. 23)

BIOMARKER FINDINGS

Tumor Mutational Burden - 23 Muts/Mb

10 Trials see p. 23

Microsatellite status - MS-Stable

THERAPIES WITH CLINICAL RELEVANCE
(IN PATIENT’S TUMOR TYPE)


Pembrolizumab	2A
Dostarlimab	

No therapies or clinical trials. See Biomarker Findings section


THERAPIES WITH CLINICAL RELEVANCE
(IN OTHER TUMOR TYPE)

Atezolizumab
Avelumab
Cemiplimab
Durvalumab
Nivolumab
Nivolumab + Ipilimumab

Biomarcadores en pacientes con cáncer de pulmón no células pequeñas



Hallmarks of cancer (2000)




1. The Hallmarks of Cancer

2. Hanahan, Douglas et al.

3. Cell, Volume 100, Issue 1, 57 - 70


Hallmarks of cancer (2011)





1. [Hallmarks of Cancer: The Next Generation](#)

2. Hanahan, Douglas et al.

3. Cell, Volume 144, Issue 5, 646 - 674









**The 2018 Nobel Prize in
Physiology or Medicine**


was awarded to


**Dr. James P. Allison and
Dr. Tasuku Honjo**

for their discoveries of molecular
mechanisms that control immune
responses, which have radically
changed cancer treatment




Aprobaciones de inmunoterapia en tumores sólidos







CAR T-cell Therapy



© 2017 Teresa Winslow LLC
U.S. Govt. has certain rights



THE NOBEL PRIZE IN CHEMISTRY 2024




David
Baker

Demis
Hassabis

John M.
Jumper

Cifras estimadas de 2022 a 2050, Hombres y mujeres, Todos los tipos de cáncer



Muchas gracias



www.marco.care/



floscomd@gmail.com



[@fedelosco](#)



Federico
Losco